Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Midomafetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midomafetamine SCHEMBL24088997 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL896602 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL30064471 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL15162286 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL29353930 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL2414825 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL25233404 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL25233250 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL31158474 | 0.97 | TAAR1 (0.94) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL2421248 | 0.97 | TAAR1 (0.94) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4015 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122016983-A | Method for detecting multiple drugs in hair | 公安部鉴定中心 | 2026-05-12 | — | — | CN | claimed |
| EP-4396305-B1 | SYNTHESIS OF MDMA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA ISOMERS | EMPATHBIO INC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260114492-A1 | ORAL DELIVERY PRODUCTS | BOLDT RUNNERS CORP (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090502-A2 | ORAL DELIVERY PRODUCTS | Boldt Runners Corporation (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4728531-A1 | BIOADAPTIVE THERAPEUTIC ENVIRONMENTS | Therapod LLC (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260097017-A1 | TASIPIMIDINE AND CYP2D6 INHIBITOR COMBINATION TREATMENT | ORION CORPORATION (FI) | 2026-04-09 | — | — | US | claimed |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | claimed |
| WO-2004054578-A1 | TREATMENT OF PSYCHOSTIMULANT ADDICTION | LEK PHARMACEUTICALS D.D. (SI) | 2004-07-01 | — | — | WO | claimed |
| US-20040121400-A1 | Method and kit for detecting, or determining, 3,4-methylenedioxymethamphetamine | NORTHERN BANK LIMITED (IE) | 2004-06-24 | — | — | US | claimed |
| US-6669937-B2 | A monoclonal antibody that specifically recognizes a stimulant or hallucinogenic drug of abuse or a metabolite, selected from d-methamphetamine, d-amphetamine, 3,4-methylenedioxymethamphetamine or derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2003-12-30 | — | — | US | claimed |
| US-20030119083-A1 | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-26 | — | — | US | claimed |
| EP-1321772-A1 | Method and kit for detecting, or determining, 3,4-methylenedioxymethamphetamine | Randox Laboratories Ltd. (GB) | 2003-06-25 | — | — | EP | claimed |
| US-6534325-B1 | Determining if a urine sample contains drugs by combining sample with antibody specific for the drug and having cross-reactivity with it; kit | ROCHE DIAGNOSTICS CORPORATION | 2003-03-18 | — | — | US | claimed |
| US-20020013372-A1 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | claimed |
| US-20010051158-A1 | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | BIOVENTURES, LLC | 2001-12-13 | — | — | US | claimed |
| WO-2001081424-A1 | MONOCLONAL ANTIBODY ANTAGONISTS FOR TREATING MEDICAL PROBLEMS ASSOCIATED WITH D-AMPHETAMINE-LIKE DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2001-11-01 | — | — | WO | claimed |
| EP-1134290-A2 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |